13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001274413
Total reported value
$143.3M
$143.3M
97 檔
54.7%
In Q2 2024, Sectoral Asset Management Inc's U.S. equity holdings reached a combined market value of $143.3M, distributed across 97 disclosed stock positions.
During Q2 2024, Sectoral Asset Management Inc's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 8.62% | +0.48% | -8.77% | |
| 2 | LENZ | Lenz Therapeutics Inc | Stock-Other | 7.62% | — | +1.47% | |
| 3 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 5.73% | +0.45% | — | |
| 4 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 5.52% | +0.49% | +15.10% | |
| 5 | MRK | Merck & Co. Inc. | Stock-Healthcare | 4.35% | -0.20% | — | |
| 6 | JNJ | Johnson & Johnson | Stock-Healthcare | 3.38% | -0.46% | +18.81% | |
| 7 | ABBV | Abbvie Inc | Stock-Healthcare | 3.13% | -0.06% | +27.70% | |
| 8 | ABT | Abbott Laboratories | Stock-Healthcare | 2.80% | -1.04% | -5.69% | |
| 9 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 2.58% | -1.12% | -14.63% | |
| 10 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 2.36% | -0.20% | +4.99% | |
| 11 | BSX | Boston Scientific CORP | Stock-Healthcare | 2.24% | -0.73% | -17.35% | |
| 12 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 2.09% | -0.47% | -20.55% | |
| 13 | PFE | Pfizer Inc | Stock-Healthcare | 2.06% | -0.18% | -4.22% | |
| 14 | GILD | Gilead Sciences Inc | Stock-Healthcare | 1.92% | -1.60% | +77.82% | |
| 15 | MDT | Medtronic plc | Stock-Healthcare | 1.90% | -0.19% | +56.50% | |
| 16 | AMGN | Amgen Inc | Stock-Healthcare | 1.87% | -0.58% | -8.61% | |
| 17 | DHR | Danaher CORP | Stock-Healthcare | 1.80% | -0.23% | — | |
| 18 | SYK | Stryker CORP | Stock-Healthcare | 1.78% | -0.03% | +94.70% | |
| 19 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 1.65% | -0.98% | +19.97% | |
| 20 | DXCM | Dexcom Inc | Stock-Healthcare | 1.48% | +1.18% | -0.77% | |
| 21 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.38% | -0.12% | -20.10% | |
| 22 | IQV | Iqvia Holdings Inc | Stock-Healthcare | 1.34% | +0.29% | +10.64% | |
| 23 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.23% | -0.23% | -32.39% | |
| 24 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 1.18% | — | -10.42% | |
| 25 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.14% | -0.44% | -29.92% | |
| 26 | BOLD | Boundless Bio Inc | Stock-Other | 1.07% | -0.62% | EXIT | |
| 27 | MRNA | Moderna Inc | Stock-Healthcare | 1.07% | — | +50.00% | |
| 28 | PCVX | Vaxcyte Inc | Stock-Other | 1.04% | — | +296.82% | |
| 29 | ICLR | ICON Public Limited Company | Stock-Healthcare | 1.02% | — | +1.07% | |
| 30 | ELV | Elevance Health Inc | Stock-Healthcare | 0.99% | — | +28.57% | |
| 31 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 0.98% | -0.38% | -11.48% | |
| 32 | CVS | Cvs Health CORP | Stock-Healthcare | 0.94% | +0.94% | NEW | |
| 33 | BNTX | Biontech Se-adr | Stock-Other | 0.89% | +1.03% | +673.48% | |
| 34 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.87% | — | -1.90% | |
| 35 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.87% | — | -21.95% | |
| 36 | GDRX | Goodrx Holdings Inc-class A | Stock-Other | 0.84% | — | -17.45% | |
| 37 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.82% | -0.39% | +15.90% | |
| 38 | PGNY | Progyny Inc | Stock-Other | 0.81% | — | -7.89% | |
| 39 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.81% | +0.52% | -13.39% | |
| 40 | NARIUSD | Inari Medical Inc | Stock-Other | 0.79% | — | -22.86% | |
| 41 | OPCH | Option Care Health Inc | Stock-Healthcare | 0.73% | — | +1.56% | |
| 42 | HUM | Humana Inc | Stock-Healthcare | 0.72% | +0.35% | NEW | |
| 43 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 0.69% | — | -11.38% | |
| 44 | STVN | Stevanato Group S.p.A. | Stock-Other | 0.66% | — | — | |
| 45 | EVH | Evolent Health Inc - A | Stock-Other | 0.65% | — | — | |
| 46 | PODD | Insulet CORP | Stock-Healthcare | 0.60% | — | -59.39% | |
| 47 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 0.59% | -0.21% | — | |
| 48 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 0.58% | — | -27.62% | |
| 49 | BIIB | Biogen Inc | Stock-Healthcare | 0.58% | -0.04% | -11.91% | |
| 50 | ✓ | Turnstone Biologics CORP | Stock-Other | 0.55% | — | — |
According to official SEC Form 13F filings, Sectoral Asset Management Inc reported a total U.S. public equity portfolio value of $143.3M across 97 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LLY, LENZ, CTNM) accounted for 54.7% of total reported equity market value during Q2 2024.
During Q2 2024, Sectoral Asset Management Inc's top holdings by market value included LLY (8.6%)、LENZ (7.6%)、CTNM (5.7%). The largest single position, LLY, represented 8.6% of total portfolio value.
In Q2 2024, Sectoral Asset Management Inc made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.